Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.23 ^USD	+7.86%		+3.52%	-18.19%

Apr. 26	Cytokinetics Appoints Sung Lee as CFO	MT
Apr. 18	Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	CI

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

February 20, 2024 at 04:30 pm EST

Vir Biotechnology, Inc. announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family.

Latest news about Vir Biotechnology, Inc.

Cytokinetics Appoints Sung Lee as CFO	Apr. 26	MT
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	Apr. 18	CI
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	Apr. 18	CI
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM	Mar. 13
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule	Mar. 05	MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	Mar. 05	CI
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	Feb. 23	MT
Vir Biotechnology, GSK Terminate Collaboration on Flu	Feb. 22	DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M	Feb. 22	MT
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA	Feb. 22	CI
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer	Feb. 20	CI
HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating	Feb. 14	MT
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23	Jan. 29	MT
Transcript : Vir Biotechnology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Vir Biotechnology to Eliminate Roles, Close Facilities to Cut Costs	Dec. 13	MT
Vir Biotechnology to cut about 75 jobs, shut some facilities	Dec. 13	RE
Transcript : Vir Biotechnology, Inc. - Special Call	Nov. 13
Transcript : Vir Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q3 Revenue $2.6M, vs. Street Est of $8.8M	Nov. 02	MT
Vir Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer	23-10-30	CI
Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD?s the Liver Meeting® 2023	23-10-11	CI

Chart Vir Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Vir Biotechnology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.23 USD

Average target price

29.5 USD

Spread / Average Target

+258.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIR BIOTECHNOLOGY, INC.	-18.19%	1.12B
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research